Electrochemotherapy as an alternative treatment option to pelvic exenteration for recurrent vulvar cancer of the perineum region
ID Vivod, Gregor (Author), ID Kovačević, Nina (Author), ID Čemažar, Maja (Author), ID Serša, Gregor (Author), ID Jesenko, Tanja (Author), ID Bošnjak, Maša (Author), ID Kranjc Brezar, Simona (Author), ID Merlo, Sebastjan (Author)

.pdfPDF - Presentation file, Download (1,09 MB)
MD5: 86B2372AC4A98D74EADBFDC19F78867D
URLURL - Source URL, Visit https://journals.sagepub.com/doi/10.1177/15330338221116489 This link opens in a new window

Objective: Pelvic exenteration in women with recurrent vulvar carcinoma is associated with high morbidity and mortality and substantial treatment costs. Because pelvic exenteration severely affects the quality of life and can lead to significant complications, other treatment modalities, such as electrochemotherapy, have been proposed. The aim of this study was to evaluate the feasibility and suitability of electrochemotherapy in the treatment of recurrent vulvar cancer. We aimed to analyze the treatment options, treatment outcomes, and complications in patients with recurrent vulvar cancer of the perineum. Methods: A retrospective analysis of patients who had undergone pelvic exenteration for vulvar cancer at the Institute of Oncology Ljubljana over a 16-year period was performed. As an experimental, less mutilating treatment, electrochemotherapy was performed on one patient with recurrent vulvar cancer involving the perineum. Comparative data analysis was performed between the group with pelvic exenteration and the patient with electrochemotherapy, comparing hospital stay, disease recurrence after treatment, survival after treatment in months, and quality of life after treatment. Results: We observed recurrence of disease in 2 patients with initial FIGO stage IIIC disease 3 months and 32 months after pelvic exenteration, and they died of the disease 15 and 38 months after pelvic exenteration. Two patients with FIGO stage IB were alive at 74 and 88 months after pelvic exenteration. One patient with initial FIGO stage IIIC was alive 12 months after treatment with electrochemotherapy with no visible signs of disease progression in the vulvar region, and the lesions had a complete response. The patient treated with electrochemotherapy was hospitalized for 4 days compared with the patients with pelvic exenteration, in whom the average hospital stay was 19.75 (± 1.68) days. Conclusion: Our experience has shown that electrochemotherapy might be a less radical alternative to pelvic exenteration, especially for patients with initially higher FIGO stages.

Keywords:vulvar cancer, electrochemotherapy, surgery, pelvic exenteration, recurrent disease
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
ZF - Faculty of Health Sciences
FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Number of pages:7 str.
Numbering:Vol. 21
PID:20.500.12556/RUL-144197 This link opens in a new window
ISSN on article:1533-0338
DOI:10.1177/15330338221116489 This link opens in a new window
COBISS.SI-ID:117591811 This link opens in a new window
Publication date in RUL:03.02.2023
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Technology in cancer research and treatment
COBISS.SI-ID:29671385 This link opens in a new window


License:CC BY 4.0, Creative Commons Attribution 4.0 International
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Keywords:rak vulve, elektrokemoterapija, kirurgija


Funder:ARRS - Slovenian Research Agency
Project number:P3-0003
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections: